According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

The Cancer Imaging (CI) Program is a transdisciplinary program that integrates imaging and engineering research with the study of cancer biology. The goals of this program are to build novel imaging ...

Microultrasonography-guided prostate biopsy proved noninferior to MRI/conventional ultrasound-fusion (MRI/US-fusion) imaging for detecting clinically significant cancer, a large randomized trial ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

Given the success of the Research Topic "Advancing Cancer Imaging Technologies: Bridging the Gap from Research to Clinical Practice", we are pleased to ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

A new editorial was published in Oncotarget , Volume 16, on March 13, 2025, titled "No disease left behind." In this editorial, Dr. Muzamil Arshad from the University of Chicago Medical Center and ...

Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...

Mobile Health Group and Mercy Radiology partnered together in 2024 to roll out Mobile Imaging – New Zealand’s first state-of-the-art mobile PET-CT unit, designed to travel across regions, ensuring ...

Tim Boreham chats with Imagion Biosystems executive chair Bob Proulx about its emerging alternative for imaging the human body. In this episode Tim chats with Imagion Biosystems (ASX:IBX) executive ...